Diabetes Mellitus, Type 2SCHOLARNCT06351748
Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)
An observational study of Diabetes Mellitus, Type 2, run by Novo Nordisk A/S at 1 site in China.
Trial summary
This study is to describe the real-world use and impact of semaglutide once-weekly (OW) among participants with type 2 diabetes mellitus (T2DM) in China. Participants diagnosed with T2DM who initiated semaglutide OW for the first time between 1 Jan 2022 (the date when semaglutide OW was listed in the National… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Diabetes Mellitus, Type 2
- What is being tested?
- Semaglutide
- How many people
- 34,238 participants
- Where
- 1 siteChina
- Study dates
- 2 Jan 2024to 29 Mar 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Participants diagnosed with T2DM who initiated semaglutide OW for the first time during the patient identification period.
Who may be able to join
- Male or female participants aged greater than or equal to (≥) 18 years on index date
- Participants with diagnosis of T2DM prior to or on index date
- Participants with initiation of semaglutide OW for the first time within the identification period
Who cannot join
- Participants with diagnosis of type 1 diabetes prior to or on index date
- Participants who were pregnant within 36 months prior to or on index date
- Participants who participated in any clinical trials within 36 months prior to or on index date which could be identified from medical records
Trial locations and contacts
1 site in 1 country.
About this study
This study is to describe the real-world use and impact of semaglutide once-weekly (OW) among participants with type 2 diabetes mellitus (T2DM) in China. Participants diagnosed with T2DM who initiated semaglutide OW for the first time between 1 Jan 2022 (the date when semaglutide OW was listed in the National Reimbursement Drug List [NRDL] in China] and 28 Feb 2023 (9 months prior to the data extraction cut-off date of 30 Nov 2023) will be included in this study. The study period will be 36 months prior to the first date of participants identification period.
- Conditions
- Diabetes Mellitus, Type 2
- Being tested
- Semaglutide
- Medical subject headings
- Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SemaglutideDrug
Also called Ozempic
Participants received semaglutide OW according to local label and to routine clinical practice at the discretion of the treating physician.
| Study group | Role | What they receive |
|---|---|---|
| Participants with T2DM | Participants diagnosed with T2DM who initiated semaglutide OW for the first time between 1 Jan 2022 (the date when semaglutide OW was listed in the National Reimbursement Drug List [NRDL] in China) and 28 Feb 2023 (9 months prior to the data extraction cut-off date of 30 Nov 2023. Receives: Drug: Semaglutide |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Haemoglobin A1c (HbA1c) level
Measured in Percentage (%).
Measured: From baseline (3 months prior to or on the index date) to 6 months
Change in HbA1c level
Measured in millimoles per mol (mmol/mol)
Measured: From baseline (3 months prior to or on the index date) to 6 months
Proportion of participants achieving HbA1c less than (<) 7.0%
Measured in percentage of participants.
Measured: At 6 months
Secondary outcomes (9)
Change in HbA1c level
Measured in %.
Measured: From baseline (3 months prior to or on the index date) to 12 months
Change in HbA1c level
Measured in mmol/mol.
Measured: From baseline (3 months prior to or on the index date) to 12 months
Proportion of participants achieving HbA1c <7.0%
Measured in percentage of participants.
Measured: At 12 months
Change in body weight
Measured in kilograms.
Measured: From baseline (3 months prior to or on the index date) to 12 months
Change in body weight
Measured in kilograms.
Measured: From baseline (3 months prior to or on the index date) to 6 months
Description of participants with different demographic characteristics
Measured: At baseline (12 months prior to or on the index date)
Description of participants with different clinical characteristics
Measured: At baseline (36 months prior to or on the index date)
Proportion of participants with different antidiabetic medications
Measured in percentage of participants.
Measured: At baseline (3 months prior to or on the index date)
Proportion of participants with different non-antidiabetic medications
Measured in percentage of participants.
Measured: At baseline (3 months prior to or on the index date)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Apr 2024
- Study start2 Jan 2024
- Primary completion29 Mar 2024
- Study completion29 Mar 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Diabetes Mellitus, Type 2Studies of the same condition, open and under way.
- More trials run by Novo Nordisk A/SThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 34,238 participants (actual)
Sponsor and investigators
- Lead sponsor
- Novo Nordisk A/S
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Transparency (dept. 2834), Study director, Novo Nordisk A/S
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06351748
- Sponsor's protocol ID
- NN9535-7877
- Other IDs
- U1111-1296-3151
- Acronym
- SCHOLAR
- Status last verified
- Apr 2025
- First submitted
- 2 Apr 2024
- Last updated
- 16 Apr 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Publications
Wang S, Dong B, Shen Z. Combined Semaglutide and Sodium-Glucose Cotransporter-2 Inhibitor Use and Metabolic Outcomes in Chinese Adults With Diabetes: Post Hoc Analysis. Diabetes Ther. 2026 Sep 28. doi: 10.1007/s13300-026-01915-y. Online ahead of print.
PubMed 42803912Wang S, Hu P, Shen Z, Chen L. Real-World Cohort Study of Semaglutide in Adults with Type 2 Diabetes Using an Electronic Health Records Database in Tianjin, China. Diabetes Ther. 2026 Apr;17(4):587-602. doi: 10.1007/s13300-026-01848-6. Epub 2026 Mar 18.
PubMed 41848818
Study at a glance
From the registry record, last updated by the sponsor on 16 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)
- ClinicalTrials.gov ID
- NCT06351748
- Acronym / sponsor ID
- SCHOLAR / NN9535-7877
- Conditions
- Diabetes Mellitus, Type 2
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 34,238 participants (actual)
- Lead sponsor
- Novo Nordisk A/SIndustry (pharma, biotech, devices)
- Study start
- 2 Jan 2024 (actual)
- Primary completion
- 29 Mar 2024 (actual)
- Study completion
- 29 Mar 2024 (actual)
- First posted
- 8 Apr 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is to describe the real-world use and impact of semaglutide once-weekly (OW) among participants with type 2 diabetes mellitus (T2DM) in China. Participants diagnosed with T2DM who initiated semaglutide OW for the first time between 1 Jan 2022 (the date when semaglutide OW was listed in the National Reimbursement Drug List [NRDL] in China] and 28 Feb 2023 (9 months prior to the data extraction cut-off date of 30 Nov 2023) will be included in this study. The study period will be 36 months prior to the first date of participants identification period.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Participants with T2DM | – | Drug: SemaglutideParticipants diagnosed with T2DM who initiated semaglutide OW for the first time between 1 Jan 2022 (the date when semaglutide OW was listed in the National Reimbursement Drug List [NRDL] in China) and 28 Feb 2023 (9 months prior to the data extraction cut-off date of 30 Nov 2023. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Participants diagnosed with T2DM who initiated semaglutide OW for the first time during the patient identification period.
Key inclusion criteria (3 listed)
- Male or female participants aged greater than or equal to (≥) 18 years on index date
- Participants with diagnosis of T2DM prior to or on index date
- Participants with initiation of semaglutide OW for the first time within the identification period
Key exclusion criteria (3 listed)
- Participants with diagnosis of type 1 diabetes prior to or on index date
- Participants who were pregnant within 36 months prior to or on index date
- Participants who participated in any clinical trials within 36 months prior to or on index date which could be identified from medical records
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SemaglutideAlso: OzempicParticipants received semaglutide OW according to local label and to routine clinical practice at the discretion of the treating physician. | Drug | Participants with T2DM |
Primary outcome
Change in Haemoglobin A1c (HbA1c) level
Time frame: From baseline (3 months prior to or on the index date) to 6 months
Measured in Percentage (%).
Change in HbA1c level
Time frame: From baseline (3 months prior to or on the index date) to 6 months
Measured in millimoles per mol (mmol/mol)
Proportion of participants achieving HbA1c less than (<) 7.0%
Time frame: At 6 months
Measured in percentage of participants.
9 secondary outcomes
Change in HbA1c level
Time frame: From baseline (3 months prior to or on the index date) to 12 months
Change in HbA1c level
Time frame: From baseline (3 months prior to or on the index date) to 12 months
Proportion of participants achieving HbA1c <7.0%
Time frame: At 12 months
Change in body weight
Time frame: From baseline (3 months prior to or on the index date) to 12 months
Change in body weight
Time frame: From baseline (3 months prior to or on the index date) to 6 months
Description of participants with different demographic characteristics
Time frame: At baseline (12 months prior to or on the index date)
Description of participants with different clinical characteristics
Time frame: At baseline (36 months prior to or on the index date)
Proportion of participants with different antidiabetic medications
Time frame: At baseline (3 months prior to or on the index date)
Proportion of participants with different non-antidiabetic medications
Time frame: At baseline (3 months prior to or on the index date)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Apr 2025.
- Derived from this study: PubMed 42803912Wang S, Dong B, Shen Z. Combined Semaglutide and Sodium-Glucose Cotransporter-2 Inhibitor Use and Metabolic Outcomes in Chinese Adults With Diabetes: Post Hoc Analysis. Diabetes Ther. 2026 Sep 28. doi: 10.1007/s13300-026-01915-y. Online ahead of print.
- Derived from this study: PubMed 41848818Wang S, Hu P, Shen Z, Chen L. Real-World Cohort Study of Semaglutide in Adults with Type 2 Diabetes Using an Electronic Health Records Database in Tianjin, China. Diabetes Ther. 2026 Apr;17(4):587-602. doi: 10.1007/s13300-026-01848-6. Epub 2026 Mar 18.
- Individual participant dataSharing planned: Yes. According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Related trials for Diabetes Mellitus, Type 2
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Transparency (dept. 2834) study director
Novo Nordisk A/S
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Diabetes Mellitus, Type 2, run by Novo Nordisk A/S at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Haemoglobin A1c (HbA1c) level (time frame: From baseline (3 months prior to or on the index date) to 6 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06351748, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Apr 2025.